Clinical Trial Update: A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for MEDI8897 evaluating safety for prevention of medically attended RSV LRTI in high-risk children; completed phases 2 and 3 with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• MEDI8897

Snippet

Sponsor: AstraZeneca | Conditions: Respiratory Syncytial Virus Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-09-21